{"id":82065,"date":"2026-05-05T15:08:10","date_gmt":"2026-05-05T09:38:10","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=82065"},"modified":"2026-05-05T15:11:11","modified_gmt":"2026-05-05T09:41:11","slug":"wockhardt-share-price-q4-fy26-pat-turnaround","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/wockhardt-share-price-q4-fy26-pat-turnaround\/","title":{"rendered":"Wockhardt Share Price Jumps 9 Percent After Q4 FY26 PAT Swings to Rs 166 Crore from Year-Ago Loss"},"content":{"rendered":"<p>Wockhardt share price jumped approximately 9% on May 5, 2026, extending gains from the Q4 FY26 results declared on May 4, where the pharmaceutical company reported a consolidated net profit of Rs 166 crore versus a net loss of Rs 25 crore in Q4 FY25. The Wockhardt share price rally represents one of the most significant post-results moves for the pharma stock in recent years, with investors re-rating the company on the back of its ongoing business transformation driven by the novel antibiotic WCK pipeline and recovery in base pharmaceutical formulations business.<\/p><p>Total income for Q4 FY26 reached Rs 1,010 crore versus Rs 913 crore in Q3 FY26, while EPS for the quarter stood at Rs 10.22 versus Rs 3.61 in Q3 FY26. The Wockhardt share price movement reflects the scale of the quarterly improvement: the swing from a Rs 25 crore loss in Q4 FY25 to a Rs 166 crore profit in Q4 FY26 represents a Rs 191 crore year-on-year quarterly improvement, one of the largest PAT swings in Wockhardt&#8217;s recent listed history. FY26 overall business growth has been described as robust by the company.<\/p><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Get Free Stock Recommendations on Univest<\/strong><\/a><\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-share-price-q4-fy26-pat-turnaround\/#Wockhardt_share_price_at_a_Glance\" title=\"Wockhardt share price at a Glance\">Wockhardt share price at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-share-price-q4-fy26-pat-turnaround\/#What_Drove_Wockhardt_Share_Price_Jump_After_Q4_FY26_Results\" title=\"What Drove Wockhardt Share Price Jump After Q4 FY26 Results\">What Drove Wockhardt Share Price Jump After Q4 FY26 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-share-price-q4-fy26-pat-turnaround\/#WCK_Novel_Antibiotic_Pipeline_is_the_Long-Term_Wockhardt_Share_Price_Catalyst\" title=\"WCK Novel Antibiotic Pipeline is the Long-Term Wockhardt Share Price Catalyst\">WCK Novel Antibiotic Pipeline is the Long-Term Wockhardt Share Price Catalyst<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-share-price-q4-fy26-pat-turnaround\/#Wockhardt_Share_Price_and_the_Drug_Resistant_Bacteria_Market_Opportunity\" title=\"Wockhardt Share Price and the Drug Resistant Bacteria Market Opportunity\">Wockhardt Share Price and the Drug Resistant Bacteria Market Opportunity<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-share-price-q4-fy26-pat-turnaround\/#Regulated_Market_Formulations_Recovery_Supporting_Wockhardt_Share_Price\" title=\"Regulated Market Formulations Recovery Supporting Wockhardt Share Price\">Regulated Market Formulations Recovery Supporting Wockhardt Share Price<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-share-price-q4-fy26-pat-turnaround\/#Wockhardt_Share_Price_Outlook_Post_Q4_FY26_Results\" title=\"Wockhardt Share Price Outlook Post Q4 FY26 Results\">Wockhardt Share Price Outlook Post Q4 FY26 Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-share-price-q4-fy26-pat-turnaround\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-share-price-q4-fy26-pat-turnaround\/#Why_did_Wockhardt_share_price_jump_9_on_May_5_2026\" title=\"Why did Wockhardt share price jump 9% on May 5, 2026?\">Why did Wockhardt share price jump 9% on May 5, 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-share-price-q4-fy26-pat-turnaround\/#What_is_Wockhardt_Q4_FY26_net_profit\" title=\"What is Wockhardt Q4 FY26 net profit?\">What is Wockhardt Q4 FY26 net profit?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-share-price-q4-fy26-pat-turnaround\/#What_is_the_WCK_novel_antibiotic_pipeline\" title=\"What is the WCK novel antibiotic pipeline?\">What is the WCK novel antibiotic pipeline?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-share-price-q4-fy26-pat-turnaround\/#Is_Wockhardt_a_good_investment_after_Q4_FY26_results\" title=\"Is Wockhardt a good investment after Q4 FY26 results?\">Is Wockhardt a good investment after Q4 FY26 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-share-price-q4-fy26-pat-turnaround\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wockhardt_share_price_at_a_Glance\"><\/span><strong>Wockhardt share price at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Value<\/strong><\/td><td><strong>Context \/ Change<\/strong><\/td><\/tr><tr><td>Q4 FY26 Consolidated PAT<\/td><td>Rs 166 crore<\/td><td>vs loss Rs 25 crore in Q4 FY25 \u2014 Rs 191 crore swing<\/td><\/tr><tr><td>Q4 FY26 Total Income<\/td><td>Rs 1,010 crore<\/td><td>vs Rs 913 crore in Q3 FY26 (+10.7% QoQ)<\/td><\/tr><tr><td>Q4 FY26 EPS<\/td><td>Rs 10.22<\/td><td>vs Rs 3.61 in Q3 FY26<\/td><\/tr><tr><td>Prior Year Q4 FY25 PAT<\/td><td>Loss Rs 25 crore<\/td><td>Base for comparison<\/td><\/tr><tr><td>Novel Antibiotic Pipeline<\/td><td>WCK series (Zaynich, Nafithromycin)<\/td><td>Drug-resistant bacteria treatment platform<\/td><\/tr><tr><td>Wockhardt Share Price Jump<\/td><td>Approximately 9%<\/td><td>May 5, 2026 post-results rally<\/td><\/tr><tr><td>FY26 Business Growth<\/td><td>Robust<\/td><td>Base formulations + novel antibiotic revenue<\/td><\/tr><\/tbody><\/table><\/figure><p>Track live stock data, analyst ratings and peer comparisons on the <a href=\"https:\/\/univest.in\/screeners\"><strong>Univest Screener<\/strong><\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Drove_Wockhardt_Share_Price_Jump_After_Q4_FY26_Results\"><\/span><strong>What Drove Wockhardt Share Price Jump After Q4 FY26 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>The Wockhardt share price jump after Q4 FY26 results is explained by the combination of three positive developments in a single quarter. First, base pharmaceutical formulations business in regulated European markets including the UK and Germany showed recovery, contributing to the revenue growth. Second, early commercial traction from novel antibiotic products in the WCK series began generating revenue, adding a high-margin incremental income stream. Third, cost rationalisation across the organisation improved operating leverage, allowing more revenue to flow through to PAT. The Wockhardt share price had been depressed for years by the expectation that the WCK pipeline would take longer to commercialise; Q4 FY26 suggests commercialisation is underway.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"WCK_Novel_Antibiotic_Pipeline_is_the_Long-Term_Wockhardt_Share_Price_Catalyst\"><\/span><strong>WCK Novel Antibiotic Pipeline is the Long-Term Wockhardt Share Price Catalyst<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The WCK series of novel antibiotics targeting drug-resistant bacterial infections is Wockhardt&#8217;s most valuable intellectual property and the primary long-term re-rating catalyst for the Wockhardt share price. Zaynich (cefepime-zidebactam) targets carbapenem-resistant bacterial infections, which represent a global healthcare crisis as bacteria develop resistance to existing antibiotics. Nafithromycin addresses macrolide-resistant respiratory infections. If these novel antibiotics receive regulatory approvals in major markets including the US FDA and EU EMA, Wockhardt would gain access to patent-protected, premium-priced antibiotic revenue streams that could be transformative for the Wockhardt share price long-term earnings profile.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wockhardt_Share_Price_and_the_Drug_Resistant_Bacteria_Market_Opportunity\"><\/span><strong>Wockhardt Share Price and the Drug Resistant Bacteria Market Opportunity<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The global antibiotic market for drug-resistant bacteria infections is valued at over $5 billion annually and growing. Wockhardt&#8217;s WCK antibiotics are specifically designed to be active against bacteria that have developed resistance to existing antibiotics, filling a critical unmet medical need. Regulatory designations like Qualified Infectious Disease Product (QIDP) and LPAD approval pathways in the US allow expedited review for novel antibiotics addressing unmet needs, which could accelerate the Wockhardt share price catalyst timeline from regulatory approvals. A major US FDA approval for Zaynich would be the single largest positive catalyst for Wockhardt share price in the company&#8217;s recent history.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Regulated_Market_Formulations_Recovery_Supporting_Wockhardt_Share_Price\"><\/span><strong>Regulated Market Formulations Recovery Supporting Wockhardt Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Beyond the WCK pipeline, Wockhardt&#8217;s base formulations business in the UK, Germany, and other European regulated markets has been recovering from the disruptions of prior years. The UK remains Wockhardt&#8217;s largest formulations market, with hospital-administered injectable products and oral solid dosage forms providing steady revenue streams. The Wockhardt share price at current levels benefits from this base formulations recovery providing an earnings floor even before any WCK novel antibiotic revenue contribution is factored in.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wockhardt_Share_Price_Outlook_Post_Q4_FY26_Results\"><\/span><strong>Wockhardt Share Price Outlook Post Q4 FY26 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Following the Q4 FY26 turnaround, the Wockhardt share price outlook for FY27 is positive. The base formulations recovery is expected to sustain, and any incremental novel antibiotic revenue from WCK series commercial expansions in European markets would add earnings upside. The key transformational catalyst for Wockhardt share price remains a US FDA approval for Zaynich or Nafithromycin, which would unlock US market access for the highest-value novel antibiotic sales. Investors should monitor the WCK regulatory filing status in the US and EU as the primary FY27 stock catalyst beyond the operational Q4 turnaround visible in current Wockhardt share price performance.<\/p><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Univest iOS App<\/strong><\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Univest Android App<\/strong><\/a> for live market updates and expert research.<\/p><p><em>Disclaimer: This article is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results. Consult a SEBI-registered financial advisor before making any investment decisions.<\/em><\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_did_Wockhardt_share_price_jump_9_on_May_5_2026\"><\/span><strong>Why did Wockhardt share price jump 9% on May 5, 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Wockhardt share price jumped approximately 9% on May 5 after Q4 FY26 results showed PAT of Rs 166 crore versus a loss of Rs 25 crore in Q4 FY25. Total income reached Rs 1,010 crore and EPS stood at Rs 10.22. The Rs 191 crore year-on-year quarterly improvement reflected base formulations recovery in European markets and early commercial traction from the WCK novel antibiotic pipeline.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Wockhardt_Q4_FY26_net_profit\"><\/span><strong>What is Wockhardt Q4 FY26 net profit?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Wockhardt Q4 FY26 consolidated PAT was Rs 166 crore, a dramatic turnaround from a loss of Rs 25 crore in Q4 FY25. This Rs 191 crore swing is one of the largest quarterly PAT improvements in Wockhardt&#8217;s recent history. Total income for Q4 FY26 was Rs 1,010 crore, up from Rs 913 crore in Q3 FY26.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_WCK_novel_antibiotic_pipeline\"><\/span><strong>What is the WCK novel antibiotic pipeline?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Wockhardt&#8217;s WCK pipeline includes Zaynich (cefepime-zidebactam) targeting carbapenem-resistant bacteria and Nafithromycin addressing macrolide-resistant respiratory infections. These novel antibiotics address drug-resistant bacteria representing a global healthcare crisis. US FDA and EU EMA regulatory approvals for these products would be the single largest transformational catalysts for Wockhardt share price.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Is_Wockhardt_a_good_investment_after_Q4_FY26_results\"><\/span><strong>Is Wockhardt a good investment after Q4 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Wockhardt share price has rallied sharply post Q4 turnaround. The base formulations recovery provides near-term earnings support, while the WCK pipeline provides transformational long-term upside on regulatory approvals. Risks include potential delays in WCK approvals and competitive pressures in European formulations markets. Consult a SEBI-registered financial advisor before making investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/why-is-ahlucont-share-price-falling-key-reasons-2026\">Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-ahlucont-share-price-falling-key-reasons-2026\">Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-nuvoco-share-price-falling-key-reasons-2026\">Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-capacite-share-price-falling-key-reasons-2026\">Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-psp-projects-share-price-falling-key-reasons-2026\">Why Is PSP Projects Share Price Falling Key Reasons 2026<\/a><\/p><p><\/p>","protected":false},"excerpt":{"rendered":"<p>Wockhardt share price jumped approximately 9% on May 5, 2026, extending gains from the Q4 FY26 results declared on May 4, where the pharmaceutical company reported a consolidated net profit of Rs 166 crore versus a net loss of Rs 25 crore in Q4 FY25. The Wockhardt share price rally represents one of the most<\/p>\n","protected":false},"author":34,"featured_media":82066,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[4132],"class_list":["post-82065","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-q4-fy26"],"metadata":{"_edit_lock":["1777976810:23"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"rank_math_primary_category":["842"],"rank_math_seo_score":["84"],"rank_math_title":["Wockhardt Share Price Jumps 9 Percent After Q4 FY26 PAT Turns to Rs 166 Crore "],"rank_math_description":["Wockhardt share price jumps 9% after Q4 FY26 PAT reaches Rs 166 crore vs loss Rs 25 crore in Q4 FY25. Total income Rs 1,010 crore. EPS Rs 10.22."],"rank_math_focus_keyword":["Wockhardt Share Price"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["82066"],"_edit_last":["23"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["10303"],"_wp_old_slug":["wockhardt-share-price-jumps-9-percent-after-q4-fy26-pat-swings-to-rs-166-crore-from-year-ago-loss-as-novel-antibiotic-pipeline-and-formulations-business-recover"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/05150719\/Wockhardt-Share-Price.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/82065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=82065"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/82065\/revisions"}],"predecessor-version":[{"id":82069,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/82065\/revisions\/82069"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/82066"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=82065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=82065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=82065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}